Influenza vaccines in low and middle income countries: A systematic review of economic evaluations

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 7, 2013, Pages 1500-1511

  Ott, Jördis J ^a,b   Breteler, Janna Klein ^a   Tam, John S ^a   Hutubessy, Raymond C W ^a   Jit, Mark ^c,d   De Boer, Michiel R ^e,f  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cost analysis; Developing countries; Economic evaluation; Influenza; Systematic review; Vaccines

Indexed keywords

INFLUENZA VACCINE;

ADOLESCENT; ADULT; AGED; CHILD; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; INFANT; INFECTION RISK; INFLUENZA VACCINATION; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MIDDLE INCOME GROUP; OUTCOME ASSESSMENT; PRESCHOOL CHILD; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEASONAL INFLUENZA; SOCIAL STATUS; SYSTEMATIC REVIEW;

COST ANALYSIS; DEVELOPING COUNTRIES; ECONOMIC EVALUATION; INFLUENZA; SYSTEMATIC REVIEW; VACCINES;

COST-BENEFIT ANALYSIS; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; OUTCOME ASSESSMENT (HEALTH CARE); PANDEMICS; QUALITY-ADJUSTED LIFE YEARS; VACCINATION;

EID: 84880891731     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.24704     Document Type: Conference Paper

References (49)

1. Nichol KL. Cost-effectiveness and socio-economic aspects of childhood influenza vaccination. Vaccine 2011; 29:7554-8; PMID:21820477; http://dx.doi.org/10.1016/j.vaccine.2011.08.015
2. Simonsen L. The global impact of influenza on morbidity and mortality. Vaccine 1999; 17(Suppl 1):S3-10; PMID:10471173; http://dx.doi.org/10.1016/S0264- 410X(99)00099-7
3. World Health Organization (WHO). Pandemic influenza A (H1N1) 2009 virus vaccine - conclusions and recommendations from the October 2009 meeting of the immunization Strategic Advisory Group of Experts. Wkly Epidemiol Rec 2009; 84:505-8; PMID:19960623
4. World Health Organization (WHO). Acute respiratory infections. Update September 2009. The A/2009 H1N1 influenza virus pandemic. Available from: http://www.who.int/vaccine-research/diseases/ari/en/index5.html. [Accessed October 8, 2012].
5. World Health Organization. Vaccines against influenza WHO position paper-November 2012. Wkly Epidemiol Rec 2012; 47:461
6. Centers for Disease Control and Prevention (CDC). Influenza and pneumococcal vaccination coverage levels among persons aged > or = 65 years-United States, 1973-1993. MMWR Morb Mortal Wkly Rep 1995; 44:506-7, 513-5; PMID:7596336
7. World Health Organization (WHO). Statement from WHO global Advisory Committee on Vaccine Safety about the safety profile of pandemic influenza A (H1N1) 2009 vaccines. Available from: http://www.who.int/csr/resources/ publications/swineflu/cp164-2009-1612-gacvs-h1n1-vaccine-safety.pdf. [Accessed September 20, 2012]
8. Fedson DS, Hirota Y, Shin HK, Cambillard PE, Kiely J, Ambrosch F, et al. Influenza vaccination in 22 developed countries: an update to 1995. Vaccine 1997; 15:1506-11; PMID:9330460; http://dx.doi.org/10.1016/S0264-410X(97)00091-1
9. Ng S, Wu P, Nishiura H, Ip DK, Lee ES, Cowling BJ. An analysis of national target groups for monovalent 2009 pandemic influenza vaccine and trivalent seasonal influenza vaccines in 2009-10 and 2010-11. BMC Infect Dis 2011; 11:230; PMID:21871096; http://dx.doi.org/10.1186/1471-2334-11-230
10. Cohen GM, Nettleman MD. Economic impact of influenza vaccination in preschool children. Pediatrics 2000; 106:973-6; PMID:11061762; http://dx.doi.org/10.1542/peds.106.5.973
11. Luce BR, Zangwill KM, Palmer CS, Mendelman PM, Yan L, Wolff MC, et al. Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children. Pediatrics 2001; 108:E24; PMID:11483834; http://dx.doi.org/10.1542/peds.108.2.e24
12. Mullooly JP, Bennett MD, Hornbrook MC, Barker WH, Williams WW, Patriarca PA, et al. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med 1994; 121:947-52; PMID:7978721; http://dx.doi.org/10.7326/0003-4819-121-12-199412150- 00008
13. Nichol KL. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. Arch Intern Med 2001; 161:749-59; PMID:11231710; http://dx.doi.org/10.1001/archinte.161.5.749
14. Nichol KL, Mallon KP, Mendelman PM. Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine. Vaccine 2003; 21:2207-17; PMID:12706712; http://dx.doi.org/10.1016/S0264-410X(03)00029-X
15. Scuffham PA, West PA. Economic evaluation of strategies for the control and management of influenza in Europe. Vaccine 2002; 20:2562-78; PMID:12057614; http://dx.doi.org/10.1016/S0264-410X(02)00154-8
16. Postma MJ, Baltussen RP, Palache AM, Wilschut JC. Further evidence for favorable cost-effectiveness of elderly influenza vaccination. Expert Rev Pharmacoecon Outcomes Res 2006; 6:215-27; PMID:20528557; http://dx.doi.org/10. 1586/14737167.6.2.215
17. Scott WG, Scott HM. Economic evaluation of vaccination against influenza in New Zealand. Pharmacoeconomics 1996; 9:51-60; PMID:10160087; http://dx.doi.org/10.2165/00019053-199609010-00006
18. Meltzer MI, Neuzil KM, Griffin MR, Fukuda K. An economic analysis of annual influenza vaccination of children. Vaccine 2005; 23:1004-14; PMID:15620473; http://dx.doi.org/10.1016/j.vaccine.2004.07.040
19. Jit M, Cromer D, Baguelin M, Stowe J, Andrews N, Miller E. The cost-effectiveness of vaccinating pregnant women against seasonal influenza in England and Wales. Vaccine 2010; 29:115-22; PMID:21055501; http://dx.doi.org/10. 1016/j.vaccine.2010.08.078
20. Skedgel C, Langley JM, MacDonald NE, Scott J, McNeil S. An incremental economic evaluation of targeted and universal influenza vaccination in pregnant women. Can J Public Health 2011; 102:445-50; PMID:22164556
21. Fitzner KA, Shortridge KF, McGhee SM, Hedley AJ. Cost-effectiveness study on influenza prevention in Hong Kong. Health Policy 2001; 56:215-34; PMID:11399347; http://dx.doi.org/10.1016/S0168-8510(00)00140-8
22. Gatwood J, Meltzer MI, Messonnier M, Ortega-Sanchez IR, Balkrishnan R, Prosser LA. Seasonal influenza vaccination of healthy working-age adults: a review of economic evaluations. Drugs 2012; 72:35-48; PMID:22191794; http://dx.doi.org/10.2165/11597310-000000000-00000
23. Myers ER, Misurski DA, Swamy GK. Influence of timing of seasonal influenza vaccination on effectiveness and cost-effectiveness in pregnancy. Am J Obstet Gynecol 2011; 204(Suppl 1):S128-40; PMID:21640230; http://dx.doi.org/10. 1016/j.ajog.2011.04.009
24. Dayan GH, Nguyen VH, Debbag R, Gómez R, Wood SC. Cost-effectiveness of influenza vaccination in high-risk children in Argentina. Vaccine 2001; 19:4204-13; PMID:11457546; http://dx.doi.org/10.1016/S0264- 410X(01)00160-8
25. Available at epocoslo.cochrane.org/lmic-databases, last update November 2010, accessed at May 5, 2011
26. Walker DG, Hutubessy R, Beutels P. WHO Guide for standardisation of economic evaluations of immunization programmes. Vaccine 2010; 28:2356-9; PMID:19567247; http://dx.doi.org/10.1016/j.vaccine.2009.06.035
27. Yoldascan E, Kurtaran B, Koyuncu M, Koyuncu E. Modeling the economic impact of pandemic influenza: a case study in Turkey. J Med Syst 2010; 34:139-45; PMID:20433052; http://dx.doi.org/10.1007/s10916-008-9225-x
28. Zubareva LA, Evdoshenko VG, Turovskaia SI, Krivchemko EI, Shall' AIa. Epidemiological and economic evaluation of the effectiveness of immunization with live influenza vaccine during the influenza epidemic of 1971-1973 in the city of Frunze. Zdravookhr Kirg 1976; 3:21-4; PMID:7895
29. Xing LH, Ge CM, Xing LJ. Cost-benefit analysis of influenza vaccination in Rizhao City, Shangdong Province, China. Chin J Biol 2008; 21:692-4
30. Nichol KL. Complications of influenza and benefits of vaccination. Vaccine 1999; 17(Suppl 1):S47-52; PMID:10471180; http://dx.doi.org/10.1016/ S0264-410X(99)00105-X
31. Wang MC, Wang TP, Yang SM. Effectiveness of 23-valent penumococcal polysaccharide and split-virus influenza vaccines to prevent respiratory diseases for elderly people. Zhongguo Yi Miao He Mian Yi 2010; 16:229-32; PMID:20726264
32. Apisarnthanarak A, Puthavathana P, Kitphati R, Auewarakul P, Mundy LM. Outbreaks of influenza A among nonvaccinated healthcare workers: implications for resource-limited settings. Infect Control Hosp Epidemiol 2008; 29:777-80; PMID:18624648; http://dx.doi.org/10.1086/588162
33. Wood SC, Alexseiv A, Nguyen VH. Effectiveness and economical impact of vaccination against influenza among a working population in Moscow. Vaccine 1999; 17(Suppl 3):S81-7; PMID:10559541
34. Ivannikov IuG, Efimenko IB, Marinich IG, Luk'ianov IuV, Naikhin AN. Evaluation of mass influenza prevention effectiveness using an inactivated chromatographic vaccine in Leningrad. Zh Mikrobiol Epidemiol Immunobiol 1980; 11:18-27; PMID:6449811
35. Sharipova IS, Kuz'minykh SI, Fel'dblium IV. An evaluation of the epidemiological and economic efficacy of immunizing adults with the Vaxigrippe vaccine. Zh Mikrobiol Epidemiol Immunobiol 1998; 4:46-9; PMID:9783400
36. At'kov OY, Azarov AV, Zhukov DA, Nicoloyannis N, Durand L. Influenza vaccination in healthy working adults in Russia: observational study of effectiveness and return on investment for the employer. Appl Health Econ Health Policy 2011; 9:89-99; PMID:21332253; http://dx.doi.org/10.2165/11538680- 000000000-00000
37. Burckel E, Ashraf T, de Sousa Filho JP, Forleo Neto E, Guarino H, Yauti C, et al. Economic impact of providing workplace influenza vaccination. A model and case study application at a Brazilian pharma-chemical company. Pharmacoeconomics 1999; 16:563-76; PMID:10662481; http://dx.doi.org/10.2165/ 00019053-199916050-00012
38. Morales A, Martinez MM, Tasset-Tisseau A, Rey E, Baron-Papillon F, Follet A. Costs and benefits of influenza vaccination and work productivity in a Colombian company from the employer's perspective. Value Health 2004; 7:433-41; PMID:15449635; http://dx.doi.org/10.1111/j.1524-4733.2004.74006.x
39. Samad AH, Usul MH, Zakaria D, Ismail R, Tasset-Tisseau A, Baron-Papillon F, et al. Workplace vaccination against influenza in Malaysia: does the employer benefit? J Occup Health 2006; 48:1-10; PMID:16484757; http://dx.doi.org/10. 1539/joh.48.1
40. Aballéa S, Chancellor J, Martin M, Wutzler P, Carrat F, Gasparini R, et al. The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model. Value Health 2007; 10:98-116; PMID:17391419; http://dx.doi.org/10.1111/j.1524-4733.2006.00157.x
41. Chicaíza-Becerra LA, García-Molina M, Ballesteros M, Gamboa O, Díaz J, Vega R. Economic evaluation of influenza vaccine applied to health personnel attending hospitalised oncological patients. Rev Salud Publica (Bogota) 2008; 10:756-66; PMID:19360224
42. Porras-Ramírez A, Alvis-Guzmán N, Rico-Mendoza A, Alvis-Estrada L, Castañeda-Orjuela CA, Velandia-González MP, et al. Cost effectiveness of influenza vaccination in children under 2 years old and elderly in Colombia. Rev Salud Publica (Bogota) 2009; 11:689-99; PMID:20339595
43. Gutiérrez JP, Bertozzi SM. Influenza vaccination in the elderly population in Mexico: economic considerations. Salud Publica Mex 2005; 47:234-9; PMID:16104466
44. Praditsuwan R, Assantachai P, Wasi C, Puthavatana P, Kositanont U. The efficacy and effectiveness of influenza vaccination among Thai elderly persons living in the community. J Med Assoc Thai 2005; 88:256-64; PMID:15962680
45. Wongsurakiat P, Lertakyamanee J, Maranetra KN, Jongriratanakul S, Sangkaew S. Economic evaluation of influenza vaccination in Thai chronic obstructive pulmonary disease patients. J Med Assoc Thai 2003; 86:497-508; PMID:12924797
46. Gao JM, Yu Q, Tang GH. Cost-benefit analysis on the strategy of social health insurance regarding vaccination against influenza in Xi'an city. Zhonghua Liu Xing Bing Xue Za Zhi 2008; 29:17-22; PMID:18785471
47. Liu M, Liu GF, Wang Y, Zhao W, Wang L, Shi W, et al. Study on the effectiveness and cost-benefit of influenza vaccine on elderly population in Beijing city. Zhonghua Liu Xing Bing Xue Za Zhi 2005; 26:412-6; PMID:16185449
48. Palache B. New vaccine approaches for seasonal and pandemic influenza. Vaccine 2008; 26:6232-6; PMID:18674583; http://dx.doi.org/10.1016/j.vaccine. 2008.07.022
49. Deogaonkar R, Hutubessy R, van der Putten I, Evers S, Jit M. Systematic review of studies evaluating the broader economic impact of vaccination in low and middle income countries. BMC Public Health 2012; 12:878; PMID:23072714; http://dx.doi.org/10.1186/1471-2458-12-878